Jane Street’s Syndax Pharmaceuticals SNDX Stock Holding History

Jane Street’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-16,200	Closed	-$378K	–	13015
2026 Q1	$378K	Sell	16,200 -17,100	-51%	-$372K	﹤0.01%	8690
2025 Q4	$700K	Sell	33,300 -6,400	-16%	-$112K	﹤0.01%	6962
2025 Q3	$611K	Buy	39,700 +5,500	+16%	+$72K	﹤0.01%	7420
2025 Q2	$320K	Buy	34,200 +13,600	+66%	+$150K	﹤0.01%	7735
2025 Q1	$253K	Buy	+20,600	New	+$291K	﹤0.01%	8091
2024 Q4	–	Sell	-39,600	Closed	-$762K	–	10503
2024 Q3	$762K	Buy	+39,600	New	+$818K	﹤0.01%	6434
2024 Q2	–	Sell	-45,200	Closed	-$1.08M	–	10133
2024 Q1	$1.08M	Buy	+45,200	New	+$1.01M	﹤0.01%	5283
2023 Q4	–	Sell	-111,900	Closed	-$1.62M	–	9757
2023 Q3	$1.62M	Buy	+111,900	New	+$2.12M	﹤0.01%	4384
2020 Q3	–	Sell	-25,000	Closed	-$371K	–	7862
2020 Q2	$371K	Buy	+25,000	New	+$381K	﹤0.01%	5515

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Jane Street's SNDX Position: Q2 2026 in Review

Jane Street sold out of Syndax Pharmaceuticals (SNDX) in Q2 2026, closing a stake of 335,531 shares — an estimated $6.98M sold.

Jane Street first reported a position in SNDX in Q2 2020 and held it in 18 quarters. The position peaked at $15.7M in Q4 2025. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Jane Street reported no remaining Syndax Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Jane Street sold 335,531 Syndax Pharmaceuticals shares in Q2 2026, an estimated $6.98M.
Jane Street first reported a position in Syndax Pharmaceuticals in Q2 2020 and held it in 18 quarters.
Jane Street's Syndax Pharmaceuticals position peaked at $15.7M in Q4 2025.
242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.